Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis

Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02686853

Enrollment

Registered

2016-02-22

Start date

2016-01-31

Completion date

Unknown

Last updated

2016-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cryptococcal Meningitis

Keywords

Intrathecal administration, Liposomal amphotericin B, Without Acquired Immune Deficiency Syndrome

Brief summary

The main purpose of this study is to observe the clinical effect of intrathecal administration of liposomal amphotericin B in Cryptococcal Meningitis without Acquired Immune Deficiency Syndrome (AIDS).

Interventions

DRUGLiposomal amphotericin B

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

14 Years to No maximum

Healthy volunteers

Inclusion criteria

* Cryptococcus neoformans are found in CSF

Exclusion criteria

* Patients with serious heart, lung, liver and renal insufficiency. * Patients who took broad-spectrum antibiotics and corticosteroids for a long-term. * Patients with AIDS or obvious immunodeficiency. * Patients with long term dialysis or intravenous catheter. * Patients with other brain organic disease such as purulent meningitis, intracranial swelling, etc.

Design outcomes

Primary

Measure	Time frame	Description
laboratory examination of cerebrospinal fluid	2 to 4 weeks	It includes routine test，biochemistry indicators and cytology ，namely white blood cell count per litre， protein（in g/l），glucose（in mmol/l）and chloride（in mmol/l）in cerebrospinal fluid ，an assessment will be assessed every week

Secondary

Measure	Time frame	Description
changes of clinical symptoms	2 to 4 weeks	headache duration, duration of fever,presence of cranial nerve damage

Other

Measure	Time frame	Description
The incidence of adverse reactions	24 hours	Lower back pain，lower extremity weakness， paraplegia，sphincter disturbance.

Contacts

Primary ContactHui Bu, MD

buhuimy1@163.com86

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026